AJOVY Brochure
Manufacturing · 11-50 Employees
View Company Info for Free
Overview
Website
www.ajovy.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About AJOVY Brochure
AJOVY is a prescription medicine designed for the preventive treatment of migraine in adults. It offers various dosing options to help reduce migraine days and improve patients' quality of life. The company focuses on providing resources and support for both healthcare professionals and patients, including instructions and safety information. AJOVY is intended for adults, and its safety and effectiveness in children have not been established.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is AJOVY Brochure your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when AJOVY Brochure launches new products
AJOVY Brochure, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once AJOVY Brochure has new funding data
Earning: See what the market has to say on AJOVY Brochure recently announced quarterly report
Check if AJOVY Brochure has recently received funding, and reach out quickly before it becomes old news!
Check out if AJOVY Brochure is spiking on competitors!
Website visits: Recent activity has been detected on your website
Click to see if AJOVY Brochure had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at AJOVY Brochure
Recommended Actions
Find VP level buyers at AJOVY Brochure
Find 2 more new buyers
Compare Similar Companies to AJOVY Brochure
Compare insights from companies similar to AJOVY Brochure, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
AJOVY Brochure
<$5M
11-50
Private
-
-
N/A
Company Profile Activity
Activity Insights
AJOVY Brochure is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
AJOVY Brochure is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about AJOVY Brochure.
AJOVY Brochure Tech Stack
A closer look at the technologies used by AJOVY Brochure
AJOVY Brochure News & Media
FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine
PARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today that the U.S. Food and Drug Administration (FDA) has approved AJOVY for the preventive treatment of episodic migraine in children and adolescent patients aged 6-17 years who weigh 45 kilograms (99 pounds) or more. With this approval, AJOVY becomes the first and only calcitonin gene-related peptide (CGRP)Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention
PARSIPPANY, N.J. and TEL AVIV, April 07, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for AJOVY® (fremanezumab-vfrm) to expand the indication to include the prevention of episodic migraine in children and adolescent patients aged 6-17 years who weigh 45 kilograms (99 pounds) or more. IfTeva to Present Data at the 2023 American Headache Society Annual Scientific Meeting Demonstrating AJOVY® (fremanezumab-vfrm) Injection Significantly Reduced Migraine and Depression Symptoms in Patients
TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that six abstracts revealing benefits of AJOVY (fremanezumab-vfrm) injection in patients with migraine will be presented at the 2023 American Headache Society (AHS) Annual Scientific Meeting, held June 15-18 in Austin, Texas. Featured data will include an oral presentation of the Phase 4 UNITE randomized clinical study, investNew Real-World Data Evaluating AJOVY® (fremanezumab-vfrm) Injection Use in Patients With Migraine Presented at 2022 American Headache Society Annual Meeting
TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced results from a U.S. retrospective study examining real-world concomitant use of AJOVY (fremanezumab-vfrm) injection and gepants in the prevention and acute treatment of migraine. The data showing a reduction in monthly migraine days with the treatment combination were presented as a late-breaking poster during the 2022 America
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding AJOVY Brochure
Sign Up For FreeTo access detailed company insights
AJOVY is a prescription medicine designed for the preventive treatment of migraine in adults. It offers various dosing options to help reduce migraine days and improve patients' quality of life. The company focuses on providing resources and support for both healthcare professionals and patients, including instructions and safety information. AJOVY... Read More
